A study of Avelumab with Axitinib Versus Sunitinib in Advanced Renal Cell Cancer (JAVELIN Renal 101)
A Phase 3, Multinational, Randomized, Open-label, Parallel-Arm Study of Avelumab (MSB0010718C) in Combination With Axitinib (INLYTA®) Versus Sunitinib (SUTENT®) Monotherapy in the First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Category & Conditions: Cancer
Medicine: BAVENCIO(AVELUMAB)
ClinicalTrials.gov Identifier (NCT): NCT02684006
Protocol ID: B9991003
PrintDownloadOpen Plain Language Summary Result: Click here